²Î¿¼ÎÄÏ×/References:
[1] Sun Z, Xu Q, Gao G, et al. Clinical observation in edaravone treatment for acute cerebral infarction[J]. Niger J Clin Pract, 2019, 22(10): 1324-1327.
[2] Chen J, Zhang W, Wu YQ, et al. Correlations of acute myocardial infarction complicated by cerebral infarction with insulin resistance, adiponectin and HMGB1[J]. Eur Rev Med Pharmacol Sci, 2019, 23(10): 4425-4431.
[3] Ago T, Matsuo R, Hata J, et al. Insulin resistance and clinical outcomes after acute ischemic stroke[J]. Neurology, 2018, 90(17): e1470-e1477.
[4] ÁºÑÅÈã,ÀîÆë¹â,³ÂÅàËÉ,µÈ.ÄÔ¹£ËÀ»¼ÕßѪÇåHcyˮƽÓëÑõ»¯Ó¦¼¤¡¢Ñ×Ö¢ºÍÒȵºËصֿ¹×´Ì¬µÄÏà¹ØÐÔÑо¿[J].Öйúҽѧ´´ÐÂ,2019,16(21):1-6.
[5] ÖлªÒ½Ñ§»áÉñ¾²¡Ñ§·Ö»áÖлªÒ½Ñ§»áÉñ¾²¡Ñ§·Ö»áÄÔѪ¹Ü²¡Ñ§×é.Öйú¼±ÐÔȱѪÐÔÄÔ×äÖÐÕïÖÎÖ¸ÄÏ2014[J].ÖлªÉñ¾¿ÆÔÓÖ¾,2015,48(4):246-257.
[6] Yaghi S, Furie KL, Viscoli CM, et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: a planned secondary analysis of the IRIS trial(insulin resistance intervention after stroke)[J]. Circulation, 2018, 137(5): 455-463.
[7] ÑîµÈ,ÅíÑåƽ,Àî˶,µÈ.¿Õ¸¹ÑªÌÇ¡¢¿Õ¸¹ÒȵºËØ¡¢ÒȵºËصֿ¹Ö¸ÊýºÍͬÐÍ°ëë×°±Ëáˮƽ¶Ô2ÐÍÌÇÄò²¡ºÏ²¢È±ÑªÐÔÄÔ×äÖз¢ÉúµÄÓ°Ïì[J].Éñ¾ËðÉËÓ빦ÄÜÖؽ¨,2019,14(12):618-621.
[8] Çñ²Êϼ,Íõׯ,ºØÀû·å,µÈ.¼±ÐÔÄÔ¹£ËÀ»¼ÕßѪÌǵ÷½ÚÊÜËðÓëÔçÆÚѪ¹ÜÐÔÈÏÖª¹¦ÄÜÕÏ°µÄÏà¹ØÐÔÑо¿[J].Õã½Ò½Ñ§,2020,42(1):73-75.
[9] ºúÇìÃÀ,¸ÇÀòÀò.ÄÔ¹£ËÀ»¼Õ߸ßÒȵºËØѪ֢ºÍ¾±¶¯ÂöÖàÑùÓ²»¯°ß¿éµÄ¹Øϵ[J].ÁÙ´²ÐÄѪ¹Ü²¡ÔÓÖ¾,2016,32(2):195-197.
[10] Deng XL, Liu Z, Wang C, et al. Insulin resistance in ischemic stroke[J]. Metab Brain Dis, 2017, 32(5): 1323-1334.
[11] Wang C, Fang XH, Wu XG, et al. Metabolic syndrome and risks of carotid atherosclerosis and cardiovascular events in community-based older adults in China[J]. Asia Pac J Clin Nutr, 2019, 28(4): 870-878.
[12] Chen W, Wang S, Lv W, et al. Causal associations of insulin resistance with coronary artery disease and ischemic stroke: a Mendelian randomization analysis[J]. BMJ Open Diabetes Res Care, 2020, 8(1): e001217.
[13] ÁÖ×Úΰ.¶¯ÂöÖàÑùÓ²»¯Tϸ°û¿Ë¡±ä»¯¼°Í¨¹ýlet-7eµ÷¿ØѪ¹ÜÄÚƤ¹¦ÄܵÄÑо¿[D].¼ÃÄÏ:ɽ¶«´óѧ,2017.
[14] Öܺ¯,»ÆÎÄʤ,ÀäÀû»ª,µÈ.Ñ×ÐÔÒò×ÓºÍÒȵºËصֿ¹Ö¸ÊýÓëÄÔ×äÖкϲ¢HÐ͸ßѪѹ»¼ÕߵĹØϵÑо¿[J].ʵÓÃÐÄÄÔ·ÎѪ¹Ü²¡ÔÓÖ¾,2020,28(5):12-17.
[15] Jiang Z, Wu YX, Gao ZQ. Correlations of C-Reactive protein(CRP), interleukin-6(IL-6), and insulin resistance with cerebral infarction in hypertensive patients[J]. Medical Science Monitor, 2019, 25(25): 1506-1511.
[16] ÂÞÓîÅô.²»Í¬½çµã³¬ÃôC·´Ó¦µ°°×ÓëÌÇÄò²¡ºÏ²¢ÄÔ¹£ËÀ»¼ÕßÒȵº¦Âϸ°û¹¦ÄܵĹØϵ[J].ÁÙ´²ºÍʵÑéҽѧÔÓÖ¾,2016,15(21):2117-2120.
[17] Huÿðþ‰Fanu A, Iancu M, B¢€laÿðþ‰Da R, et al. Predicting functional outcome of ischemic stroke patients in Romania based on plasma CRP, sTNFR-1, D-Dimers, NGAL and NSE measured using a biochip array[J]. Acta Pharmacol Sin, 2018, 39(7): 1228-1236.
[18] Li J, Zhou F, Wu FX. Relationship between homocysteine level and prognosis of elderly patients with acute ischemic stroke treated by thrombolysis with recombinant tissue plasminogen activator[J]. World J Clin Cases, 2019, 7(22): 3751-3756.
[19] ºÎÆäʤ,Íõ°®Æ¼,ÍõÁúº£.ºì»¨»ÆÉ«Ëض԰éÓ¦¼¤ÐÔ¸ßѪÌÇÄÔ¹£ËÀ»¼ÕßÌÇ´úл¡¢C-ëÄˮƽ¼°ÄýѪ¹¦ÄܵÄÓ°Ïì[J].ÁÙ´²ºÍʵÑéҽѧÔÓÖ¾,2019,18(5):504-508.
[20] ×Þϸƽ,ÎâÀö»ª,Íõ³¤Ææ,µÈ.ѪÇåͬÐÍ°ëë×°±Ëá¡¢ÄòËáºÍѪ½¬ÏËάµ°°×ÔˮƽÓë2ÐÍÌÇÄò²¡ºÏ²¢ÄÔ¹£ÈûÏà¹ØÐÔÑо¿[J].ʵÑéÓë¼ìÑéҽѧ,2018,36(5):730-733.
[21] ÉÛÁèÔÆ,³ÂºóÇÚ,ºÎÃô,µÈ.ȱѪÐÔÄÔ×äÖл¼ÕßÒȵºËصֿ¹Ë®Æ½ÓëÂÄÚ¶¯ÂöÏÁյĹØϵ¼°Ó°ÏìÒòËØ·ÖÎö[J].°²»Õҽѧ,2017,38(9):1174-1176.